Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis
Identifieur interne : 000383 ( Pmc/Corpus ); précédent : 000382; suivant : 000384Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis
Auteurs : Masaru Iwai ; Masatsugu HoriuchiSource :
- Hypertension Research [ 0916-9636 ] ; 2009.
Abstract
Recent studies have established a new regulatory axis in the renin–angiotensin system (RAS). In this axis, angiotensin (Ang)-(1–7) is finally produced from Ang I or Ang II by the catalytic activity of angiotensin-converting enzyme 2 (ACE2). Ang-(1–7) shows actions different from those of AT1 receptor stimulation, such as vasodilatation, natriuresis, anti-proliferation and an increase in the bradykinin–NO (nitric oxide) system. As the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I, this axis is possibly acting as a counter-regulatory system against the ACE/Ang II/AT1 receptor axis. The signaling pathway of the ACE2–Ang-(1–7) axis has not yet been totally and clearly understood. However, a recent report suggests that the Mas oncogene acts as a receptor for Ang-(1–7). Intracellular signaling through Mas is not clear yet. Several factors such as Akt phosphorylation, protein kinase C activation and mitogen-activated protein (MAP) kinase inhibition seem to be involved in this signaling pathway. Further investigations are needed to clarify the regulation and mechanism of action of ACE2 and Ang-(1–7). However, this second axis through ACE2 and Ang-(1–7) in RAS can be an important target for the therapy of cardiovascular and metabolic disorders.
Url:
DOI: 10.1038/hr.2009.74
PubMed: 19461648
PubMed Central: 7091931
Links to Exploration step
PMC:7091931Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT<sub>1</sub> receptor axis <italic>vs</italic>. ACE2–angiotensin-(1–7)–Mas receptor axis</title><author><name sortKey="Iwai, Masaru" sort="Iwai, Masaru" uniqKey="Iwai M" first="Masaru" last="Iwai">Masaru Iwai</name><affiliation><nlm:aff id="Aff1"></nlm:aff></affiliation></author><author><name sortKey="Horiuchi, Masatsugu" sort="Horiuchi, Masatsugu" uniqKey="Horiuchi M" first="Masatsugu" last="Horiuchi">Masatsugu Horiuchi</name><affiliation><nlm:aff id="Aff1"></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19461648</idno><idno type="pmc">7091931</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091931</idno><idno type="RBID">PMC:7091931</idno><idno type="doi">10.1038/hr.2009.74</idno><date when="2009">2009</date><idno type="wicri:Area/Pmc/Corpus">000383</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000383</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT<sub>1</sub> receptor axis <italic>vs</italic>. ACE2–angiotensin-(1–7)–Mas receptor axis</title><author><name sortKey="Iwai, Masaru" sort="Iwai, Masaru" uniqKey="Iwai M" first="Masaru" last="Iwai">Masaru Iwai</name><affiliation><nlm:aff id="Aff1"></nlm:aff></affiliation></author><author><name sortKey="Horiuchi, Masatsugu" sort="Horiuchi, Masatsugu" uniqKey="Horiuchi M" first="Masatsugu" last="Horiuchi">Masatsugu Horiuchi</name><affiliation><nlm:aff id="Aff1"></nlm:aff></affiliation></author></analytic><series><title level="j">Hypertension Research</title><idno type="ISSN">0916-9636</idno><idno type="eISSN">1348-4214</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="Par1">Recent studies have established a new regulatory axis in the renin–angiotensin system (RAS). In this axis, angiotensin (Ang)-(1–7) is finally produced from Ang I or Ang II by the catalytic activity of angiotensin-converting enzyme 2 (ACE2). Ang-(1–7) shows actions different from those of AT<sub>1</sub> receptor stimulation, such as vasodilatation, natriuresis, anti-proliferation and an increase in the bradykinin–NO (nitric oxide) system. As the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I, this axis is possibly acting as a counter-regulatory system against the ACE/Ang II/AT<sub>1</sub> receptor axis. The signaling pathway of the ACE2–Ang-(1–7) axis has not yet been totally and clearly understood. However, a recent report suggests that the Mas oncogene acts as a receptor for Ang-(1–7). Intracellular signaling through Mas is not clear yet. Several factors such as Akt phosphorylation, protein kinase C activation and mitogen-activated protein (MAP) kinase inhibition seem to be involved in this signaling pathway. Further investigations are needed to clarify the regulation and mechanism of action of ACE2 and Ang-(1–7). However, this second axis through ACE2 and Ang-(1–7) in RAS can be an important target for the therapy of cardiovascular and metabolic disorders.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="De Gasparo, M" uniqKey="De Gasparo M">M de Gasparo</name></author><author><name sortKey="Catt, Kj" uniqKey="Catt K">KJ Catt</name></author><author><name sortKey="Inagami, T" uniqKey="Inagami T">T Inagami</name></author><author><name sortKey="Wright, Jw" uniqKey="Wright J">JW Wright</name></author><author><name sortKey="Unger, T" uniqKey="Unger T">T Unger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Daviet, L" uniqKey="Daviet L">L Daviet</name></author><author><name sortKey="Lehtonen, Jy" uniqKey="Lehtonen J">JY Lehtonen</name></author><author><name sortKey="Tamura, K" uniqKey="Tamura K">K Tamura</name></author><author><name sortKey="Griese, Dp" uniqKey="Griese D">DP Griese</name></author><author><name sortKey="Horiuchi, M" uniqKey="Horiuchi M">M Horiuchi</name></author><author><name sortKey="Dzau, Vj" uniqKey="Dzau V">VJ Dzau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nouet, S" uniqKey="Nouet S">S Nouet</name></author><author><name sortKey="Amzallag, N" uniqKey="Amzallag N">N Amzallag</name></author><author><name sortKey="Li, Jm" uniqKey="Li J">JM Li</name></author><author><name sortKey="Louis, S" uniqKey="Louis S">S Louis</name></author><author><name sortKey="Seitz, I" uniqKey="Seitz I">I Seitz</name></author><author><name sortKey="Cui, Tx" uniqKey="Cui T">TX Cui</name></author><author><name sortKey="Alleaume, Am" uniqKey="Alleaume A">AM Alleaume</name></author><author><name sortKey="Di Benedetto, M" uniqKey="Di Benedetto M">M Di Benedetto</name></author><author><name sortKey="Boden, C" uniqKey="Boden C">C Boden</name></author><author><name sortKey="Masson, M" uniqKey="Masson M">M Masson</name></author><author><name sortKey="Strosberg, Ad" uniqKey="Strosberg A">AD Strosberg</name></author><author><name sortKey="Horiuchi, M" uniqKey="Horiuchi M">M Horiuchi</name></author><author><name sortKey="Couraud, Po" uniqKey="Couraud P">PO Couraud</name></author><author><name sortKey="Nahmias, C" uniqKey="Nahmias C">C Nahmias</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dzau, V" uniqKey="Dzau V">V Dzau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kaschina, E" uniqKey="Kaschina E">E Kaschina</name></author><author><name sortKey="Grzesiak, A" uniqKey="Grzesiak A">A Grzesiak</name></author><author><name sortKey="Li, J" uniqKey="Li J">J Li</name></author><author><name sortKey="Foryst Ludwig, A" uniqKey="Foryst Ludwig A">A Foryst-Ludwig</name></author><author><name sortKey="Timm, M" uniqKey="Timm M">M Timm</name></author><author><name sortKey="Rompe, F" uniqKey="Rompe F">F Rompe</name></author><author><name sortKey="Sommerfeld, M" uniqKey="Sommerfeld M">M Sommerfeld</name></author><author><name sortKey="Kemnitz, Ur" uniqKey="Kemnitz U">UR Kemnitz</name></author><author><name sortKey="Curato, C" uniqKey="Curato C">C Curato</name></author><author><name sortKey="Namsolleck, P" uniqKey="Namsolleck P">P Namsolleck</name></author><author><name sortKey="Tschope, C" uniqKey="Tschope C">C Tschöpe</name></author><author><name sortKey="Hallberg, A" uniqKey="Hallberg A">A Hallberg</name></author><author><name sortKey="Alterman, M" uniqKey="Alterman M">M Alterman</name></author><author><name sortKey="Hucko, T" uniqKey="Hucko T">T Hucko</name></author><author><name sortKey="Paetsch, I" uniqKey="Paetsch I">I Paetsch</name></author><author><name sortKey="Dietrich, T" uniqKey="Dietrich T">T Dietrich</name></author><author><name sortKey="Schnackenburg, B" uniqKey="Schnackenburg B">B Schnackenburg</name></author><author><name sortKey="Graf, K" uniqKey="Graf K">K Graf</name></author><author><name sortKey="Dahlof, B" uniqKey="Dahlof B">B Dahlöf</name></author><author><name sortKey="Kintscher, U" uniqKey="Kintscher U">U Kintscher</name></author><author><name sortKey="Unger, T" uniqKey="Unger T">T Unger</name></author><author><name sortKey="Steckelings, Um" uniqKey="Steckelings U">UM Steckelings</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tipnis, Sr" uniqKey="Tipnis S">SR Tipnis</name></author><author><name sortKey="Hooper, Nm" uniqKey="Hooper N">NM Hooper</name></author><author><name sortKey="Hyde, R" uniqKey="Hyde R">R Hyde</name></author><author><name sortKey="Karran, E" uniqKey="Karran E">E Karran</name></author><author><name sortKey="Christie, G" uniqKey="Christie G">G Christie</name></author><author><name sortKey="Turner, Aj" uniqKey="Turner A">AJ Turner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Santos, Ra" uniqKey="Santos R">RA Santos</name></author><author><name sortKey="Ferreira, Aj" uniqKey="Ferreira A">AJ Ferreira</name></author><author><name sortKey="E Silva, Ac" uniqKey="E Silva A">AC E Silva</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Elliott, Wj" uniqKey="Elliott W">WJ Elliott</name></author><author><name sortKey="Meyer, Pm" uniqKey="Meyer P">PM Meyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Murphy, Tj" uniqKey="Murphy T">TJ Murphy</name></author><author><name sortKey="Alexander, Rw" uniqKey="Alexander R">RW Alexander</name></author><author><name sortKey="Griendling, Kk" uniqKey="Griendling K">KK Griendling</name></author><author><name sortKey="Runge, Ms" uniqKey="Runge M">MS Runge</name></author><author><name sortKey="Bernstein, Ke" uniqKey="Bernstein K">KE Bernstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dzau, Vj" uniqKey="Dzau V">VJ Dzau</name></author><author><name sortKey="Antman, Em" uniqKey="Antman E">EM Antman</name></author><author><name sortKey="Black, Hr" uniqKey="Black H">HR Black</name></author><author><name sortKey="Hayes, Dl" uniqKey="Hayes D">DL Hayes</name></author><author><name sortKey="Manson, Je" uniqKey="Manson J">JE Manson</name></author><author><name sortKey="Plutzky, J" uniqKey="Plutzky J">J Plutzky</name></author><author><name sortKey="Popma, Jj" uniqKey="Popma J">JJ Popma</name></author><author><name sortKey="Stevenson, W" uniqKey="Stevenson W">W Stevenson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dzau, Vj" uniqKey="Dzau V">VJ Dzau</name></author><author><name sortKey="Antman, Em" uniqKey="Antman E">EM Antman</name></author><author><name sortKey="Black, Hr" uniqKey="Black H">HR Black</name></author><author><name sortKey="Hayes, Dl" uniqKey="Hayes D">DL Hayes</name></author><author><name sortKey="Manson, Je" uniqKey="Manson J">JE Manson</name></author><author><name sortKey="Plutzky, J" uniqKey="Plutzky J">J Plutzky</name></author><author><name sortKey="Popma, Jj" uniqKey="Popma J">JJ Popma</name></author><author><name sortKey="Stevenson, W" uniqKey="Stevenson W">W Stevenson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benigni, A" uniqKey="Benigni A">A Benigni</name></author><author><name sortKey="Corna, D" uniqKey="Corna D">D Corna</name></author><author><name sortKey="Zoja, C" uniqKey="Zoja C">C Zoja</name></author><author><name sortKey="Sonzogni, A" uniqKey="Sonzogni A">A Sonzogni</name></author><author><name sortKey="Latini, R" uniqKey="Latini R">R Latini</name></author><author><name sortKey="Salio, M" uniqKey="Salio M">M Salio</name></author><author><name sortKey="Conti, S" uniqKey="Conti S">S Conti</name></author><author><name sortKey="Rottoli, D" uniqKey="Rottoli D">D Rottoli</name></author><author><name sortKey="Longaretti, L" uniqKey="Longaretti L">L Longaretti</name></author><author><name sortKey="Cassis, P" uniqKey="Cassis P">P Cassis</name></author><author><name sortKey="Morigi, M" uniqKey="Morigi M">M Morigi</name></author><author><name sortKey="Coffman, Tm" uniqKey="Coffman T">TM Coffman</name></author><author><name sortKey="Remuzzi, G" uniqKey="Remuzzi G">G Remuzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Horiuchi, M" uniqKey="Horiuchi M">M Horiuchi</name></author><author><name sortKey="Hayashida, W" uniqKey="Hayashida W">W Hayashida</name></author><author><name sortKey="Akishita, M" uniqKey="Akishita M">M Akishita</name></author><author><name sortKey="Tamura, K" uniqKey="Tamura K">K Tamura</name></author><author><name sortKey="Daviet, L" uniqKey="Daviet L">L Daviet</name></author><author><name sortKey="Lehtonen, Jy" uniqKey="Lehtonen J">JY Lehtonen</name></author><author><name sortKey="Dzau, Vj" uniqKey="Dzau V">VJ Dzau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jones, Es" uniqKey="Jones E">ES Jones</name></author><author><name sortKey="Vinh, A" uniqKey="Vinh A">A Vinh</name></author><author><name sortKey="Mccarthy, Ca" uniqKey="Mccarthy C">CA McCarthy</name></author><author><name sortKey="Gaspari, Ta" uniqKey="Gaspari T">TA Gaspari</name></author><author><name sortKey="Widdop, Re" uniqKey="Widdop R">RE Widdop</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carey, Rm" uniqKey="Carey R">RM Carey</name></author><author><name sortKey="Padia, Sh" uniqKey="Padia S">SH Padia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Donoghue, M" uniqKey="Donoghue M">M Donoghue</name></author><author><name sortKey="Hsieh, F" uniqKey="Hsieh F">F Hsieh</name></author><author><name sortKey="Baronas, E" uniqKey="Baronas E">E Baronas</name></author><author><name sortKey="Godbout, K" uniqKey="Godbout K">K Godbout</name></author><author><name sortKey="Gosselin, M" uniqKey="Gosselin M">M Gosselin</name></author><author><name sortKey="Stagliano, N" uniqKey="Stagliano N">N Stagliano</name></author><author><name sortKey="Donovan, M" uniqKey="Donovan M">M Donovan</name></author><author><name sortKey="Woolf, B" uniqKey="Woolf B">B Woolf</name></author><author><name sortKey="Robison, K" uniqKey="Robison K">K Robison</name></author><author><name sortKey="Jeyaseelan, R" uniqKey="Jeyaseelan R">R Jeyaseelan</name></author><author><name sortKey="Breitbart, Re" uniqKey="Breitbart R">RE Breitbart</name></author><author><name sortKey="Acton, S" uniqKey="Acton S">S Acton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vickers, C" uniqKey="Vickers C">C Vickers</name></author><author><name sortKey="Hales, P" uniqKey="Hales P">P Hales</name></author><author><name sortKey="Kaushik, V" uniqKey="Kaushik V">V Kaushik</name></author><author><name sortKey="Dick, L" uniqKey="Dick L">L Dick</name></author><author><name sortKey="Gavin, J" uniqKey="Gavin J">J Gavin</name></author><author><name sortKey="Tang, J" uniqKey="Tang J">J Tang</name></author><author><name sortKey="Godbout, K" uniqKey="Godbout K">K Godbout</name></author><author><name sortKey="Parsons, T" uniqKey="Parsons T">T Parsons</name></author><author><name sortKey="Baronas, E" uniqKey="Baronas E">E Baronas</name></author><author><name sortKey="Hsieh, F" uniqKey="Hsieh F">F Hsieh</name></author><author><name sortKey="Acton, S" uniqKey="Acton S">S Acton</name></author><author><name sortKey="Patane, M" uniqKey="Patane M">M Patane</name></author><author><name sortKey="Nichols, A" uniqKey="Nichols A">A Nichols</name></author><author><name sortKey="Tummino, P" uniqKey="Tummino P">P Tummino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferrario, Cm" uniqKey="Ferrario C">CM Ferrario</name></author><author><name sortKey="Chappell, Mc" uniqKey="Chappell M">MC Chappell</name></author><author><name sortKey="Tallant, Ea" uniqKey="Tallant E">EA Tallant</name></author><author><name sortKey="Brosnihan, Kb" uniqKey="Brosnihan K">KB Brosnihan</name></author><author><name sortKey="Diz, Di" uniqKey="Diz D">DI Diz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roks, Aj" uniqKey="Roks A">AJ Roks</name></author><author><name sortKey="Van Geel, Pp" uniqKey="Van Geel P">PP van Geel</name></author><author><name sortKey="Pinto, Ym" uniqKey="Pinto Y">YM Pinto</name></author><author><name sortKey="Buikema, H" uniqKey="Buikema H">H Buikema</name></author><author><name sortKey="Henning, Rh" uniqKey="Henning R">RH Henning</name></author><author><name sortKey="De Zeeuw, D" uniqKey="De Zeeuw D">D de Zeeuw</name></author><author><name sortKey="Van Gilst, Wh" uniqKey="Van Gilst W">WH van Gilst</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brosnihihan, Kb" uniqKey="Brosnihihan K">KB Brosnihihan</name></author><author><name sortKey="Li, P" uniqKey="Li P">P Li</name></author><author><name sortKey="Ferrario, Cm" uniqKey="Ferrario C">CM Ferrario</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yamamoto, K" uniqKey="Yamamoto K">K Yamamoto</name></author><author><name sortKey="Ohishi, M" uniqKey="Ohishi M">M Ohishi</name></author><author><name sortKey="Katsuya, T" uniqKey="Katsuya T">T Katsuya</name></author><author><name sortKey="Ito, N" uniqKey="Ito N">N Ito</name></author><author><name sortKey="Ikushima, M" uniqKey="Ikushima M">M Ikushima</name></author><author><name sortKey="Kaibe, M" uniqKey="Kaibe M">M Kaibe</name></author><author><name sortKey="Tatara, Y" uniqKey="Tatara Y">Y Tatara</name></author><author><name sortKey="Shiota, A" uniqKey="Shiota A">A Shiota</name></author><author><name sortKey="Sugano, S" uniqKey="Sugano S">S Sugano</name></author><author><name sortKey="Takeda, S" uniqKey="Takeda S">S Takeda</name></author><author><name sortKey="Rakugi, H" uniqKey="Rakugi H">H Rakugi</name></author><author><name sortKey="Ogihara, T" uniqKey="Ogihara T">T Ogihara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ebermann, L" uniqKey="Ebermann L">L Ebermann</name></author><author><name sortKey="Spillmann, F" uniqKey="Spillmann F">F Spillmann</name></author><author><name sortKey="Sidiropoulos, M" uniqKey="Sidiropoulos M">M Sidiropoulos</name></author><author><name sortKey="Escher, F" uniqKey="Escher F">F Escher</name></author><author><name sortKey="Heringer Walther, S" uniqKey="Heringer Walther S">S Heringer-Walther</name></author><author><name sortKey="Schultheiss, Hp" uniqKey="Schultheiss H">HP Schultheiss</name></author><author><name sortKey="Tschope, C" uniqKey="Tschope C">C Tschöpe</name></author><author><name sortKey="Walther, T" uniqKey="Walther T">T Walther</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gorelik, G" uniqKey="Gorelik G">G Gorelik</name></author><author><name sortKey="Carbini, La" uniqKey="Carbini L">LA Carbini</name></author><author><name sortKey="Scicli, Ag" uniqKey="Scicli A">AG Scicli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deddish, Pa" uniqKey="Deddish P">PA Deddish</name></author><author><name sortKey="Marcic, B" uniqKey="Marcic B">B Marcic</name></author><author><name sortKey="Jackman, Hl" uniqKey="Jackman H">HL Jackman</name></author><author><name sortKey="Wang, H Z" uniqKey="Wang H">H-Z Wang</name></author><author><name sortKey="Skidgel, Ra" uniqKey="Skidgel R">RA Skidgel</name></author><author><name sortKey="Erdos, Eg" uniqKey="Erdos E">EG Erdos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Minshall, Rd" uniqKey="Minshall R">RD Minshall</name></author><author><name sortKey="Tan, F" uniqKey="Tan F">F Tan</name></author><author><name sortKey="Nakamura, F" uniqKey="Nakamura F">F Nakamura</name></author><author><name sortKey="Rabito, Sf" uniqKey="Rabito S">SF Rabito</name></author><author><name sortKey="Becker, Rp" uniqKey="Becker R">RP Becker</name></author><author><name sortKey="Marcic, B" uniqKey="Marcic B">B Marcic</name></author><author><name sortKey="Erdos, Eg" uniqKey="Erdos E">EG Erdös</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benzing, T" uniqKey="Benzing T">T Benzing</name></author><author><name sortKey="Fleming, I" uniqKey="Fleming I">I Fleming</name></author><author><name sortKey="Blaukat, A" uniqKey="Blaukat A">A Blaukat</name></author><author><name sortKey="Muller Esterl, W" uniqKey="Muller Esterl W">W Muller-Esterl</name></author><author><name sortKey="Busse, R" uniqKey="Busse R">R Busse</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Danser, Ahj" uniqKey="Danser A">AHJ Danser</name></author><author><name sortKey="Tom, B" uniqKey="Tom B">B Tom</name></author><author><name sortKey="De Vries, R" uniqKey="De Vries R">R de Vries</name></author><author><name sortKey="Saxena, Pr" uniqKey="Saxena P">PR Saxena</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ishiyama, Y" uniqKey="Ishiyama Y">Y Ishiyama</name></author><author><name sortKey="Gallagher, Pe" uniqKey="Gallagher P">PE Gallagher</name></author><author><name sortKey="Averill, Db" uniqKey="Averill D">DB Averill</name></author><author><name sortKey="Tallant, Ea" uniqKey="Tallant E">EA Tallant</name></author><author><name sortKey="Brosnihan, Kb" uniqKey="Brosnihan K">KB Brosnihan</name></author><author><name sortKey="Ferrario, Cm" uniqKey="Ferrario C">CM Ferrario</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Agata, J" uniqKey="Agata J">J Agata</name></author><author><name sortKey="Ura, N" uniqKey="Ura N">N Ura</name></author><author><name sortKey="Yoshida, H" uniqKey="Yoshida H">H Yoshida</name></author><author><name sortKey="Shinshi, Y" uniqKey="Shinshi Y">Y Shinshi</name></author><author><name sortKey="Sasaki, H" uniqKey="Sasaki H">H Sasaki</name></author><author><name sortKey="Hyakkoku, M" uniqKey="Hyakkoku M">M Hyakkoku</name></author><author><name sortKey="Taniguchi, S" uniqKey="Taniguchi S">S Taniguchi</name></author><author><name sortKey="Shimamoto, K" uniqKey="Shimamoto K">K Shimamoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Imai, Y" uniqKey="Imai Y">Y Imai</name></author><author><name sortKey="Kuba, K" uniqKey="Kuba K">K Kuba</name></author><author><name sortKey="Penninger, Jm" uniqKey="Penninger J">JM Penninger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kuba, K" uniqKey="Kuba K">K Kuba</name></author><author><name sortKey="Imai, Y" uniqKey="Imai Y">Y Imai</name></author><author><name sortKey="Rao, S" uniqKey="Rao S">S Rao</name></author><author><name sortKey="Jiang, C" uniqKey="Jiang C">C Jiang</name></author><author><name sortKey="Penninger, Jm" uniqKey="Penninger J">JM Penninger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Santos, Ra" uniqKey="Santos R">RA Santos</name></author><author><name sortKey="Simoes E Silva, Ac" uniqKey="Simoes E Silva A">AC Simoes e Silva</name></author><author><name sortKey="Maric, C" uniqKey="Maric C">C Maric</name></author><author><name sortKey="Silva, Dm" uniqKey="Silva D">DM Silva</name></author><author><name sortKey="Machado, Rp" uniqKey="Machado R">RP Machado</name></author><author><name sortKey="De Buhr, I" uniqKey="De Buhr I">I de Buhr</name></author><author><name sortKey="Heringer Walther, S" uniqKey="Heringer Walther S">S Heringer-Walther</name></author><author><name sortKey="Pinheiro, Sv" uniqKey="Pinheiro S">SV Pinheiro</name></author><author><name sortKey="Lopes, Mt" uniqKey="Lopes M">MT Lopes</name></author><author><name sortKey="Bader, M" uniqKey="Bader M">M Bader</name></author><author><name sortKey="Mendes, Ep" uniqKey="Mendes E">EP Mendes</name></author><author><name sortKey="Lemos, Vs" uniqKey="Lemos V">VS Lemos</name></author><author><name sortKey="Campagnole Santos, Mj" uniqKey="Campagnole Santos M">MJ Campagnole-Santos</name></author><author><name sortKey="Schultheiss, Hp" uniqKey="Schultheiss H">HP Schultheiss</name></author><author><name sortKey="Speth, R" uniqKey="Speth R">R Speth</name></author><author><name sortKey="Walther, T" uniqKey="Walther T">T Walther</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Santos, Ra" uniqKey="Santos R">RA Santos</name></author><author><name sortKey="Ferreira, Aj" uniqKey="Ferreira A">AJ Ferreira</name></author><author><name sortKey="E Silva, Ac" uniqKey="E Silva A">AC E Silva</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Villar, Aj" uniqKey="Villar A">AJ Villar</name></author><author><name sortKey="Pedersen, Ra" uniqKey="Pedersen R">RA Pedersen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Metzger, R" uniqKey="Metzger R">R Metzger</name></author><author><name sortKey="Bader, M" uniqKey="Bader M">M Bader</name></author><author><name sortKey="Ludwig, T" uniqKey="Ludwig T">T Ludwig</name></author><author><name sortKey="Berberich, C" uniqKey="Berberich C">C Berberich</name></author><author><name sortKey="Bunnemann, B" uniqKey="Bunnemann B">B Bunnemann</name></author><author><name sortKey="Ganten, D" uniqKey="Ganten D">D Ganten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Santos, Ra" uniqKey="Santos R">RA Santos</name></author><author><name sortKey="Castro, Ch" uniqKey="Castro C">CH Castro</name></author><author><name sortKey="Gava, E" uniqKey="Gava E">E Gava</name></author><author><name sortKey="Pinheiro, Sv" uniqKey="Pinheiro S">SV Pinheiro</name></author><author><name sortKey="Almeida, Ap" uniqKey="Almeida A">AP Almeida</name></author><author><name sortKey="Paula, Rd" uniqKey="Paula R">RD Paula</name></author><author><name sortKey="Cruz, Js" uniqKey="Cruz J">JS Cruz</name></author><author><name sortKey="Ramos, As" uniqKey="Ramos A">AS Ramos</name></author><author><name sortKey="Rosa, Kt" uniqKey="Rosa K">KT Rosa</name></author><author><name sortKey="Irigoyen, Mc" uniqKey="Irigoyen M">MC Irigoyen</name></author><author><name sortKey="Bader, M" uniqKey="Bader M">M Bader</name></author><author><name sortKey="Alenina, N" uniqKey="Alenina N">N Alenina</name></author><author><name sortKey="Kitten, Gt" uniqKey="Kitten G">GT Kitten</name></author><author><name sortKey="Ferreira, Aj" uniqKey="Ferreira A">AJ Ferreira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Castro, Ch" uniqKey="Castro C">CH Castro</name></author><author><name sortKey="Santos, Ra" uniqKey="Santos R">RA Santos</name></author><author><name sortKey="Ferreira, Aj" uniqKey="Ferreira A">AJ Ferreira</name></author><author><name sortKey="Bader, M" uniqKey="Bader M">M Bader</name></author><author><name sortKey="Alenina, N" uniqKey="Alenina N">N Alenina</name></author><author><name sortKey="Almeida, Ap" uniqKey="Almeida A">AP Almeida</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tallant, Ea" uniqKey="Tallant E">EA Tallant</name></author><author><name sortKey="Ferrario, Cm" uniqKey="Ferrario C">CM Ferrario</name></author><author><name sortKey="Gallagher, Pe" uniqKey="Gallagher P">PE Gallagher</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Hypertens Res</journal-id><journal-id journal-id-type="iso-abbrev">Hypertens. Res</journal-id><journal-title-group><journal-title>Hypertension Research</journal-title></journal-title-group><issn pub-type="ppub">0916-9636</issn><issn pub-type="epub">1348-4214</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19461648</article-id><article-id pub-id-type="pmc">7091931</article-id><article-id pub-id-type="publisher-id">BFhr200974</article-id><article-id pub-id-type="doi">10.1038/hr.2009.74</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT<sub>1</sub> receptor axis <italic>vs</italic>. ACE2–angiotensin-(1–7)–Mas receptor axis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Iwai</surname><given-names>Masaru</given-names></name><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Horiuchi</surname><given-names>Masatsugu</given-names></name><address><email>horiuchi@m.ehime-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.255464.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 1011 3808</institution-id><institution>Department of Molecular Cardiovascular Biology and Pharmacology,</institution><institution>Ehime University Graduate School of Medicine, Shitsukawa, Tohon, Ehime, Japan,</institution></institution-wrap>,</aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>5</month><year>2009</year></pub-date><pub-date pub-type="ppub"><year>2009</year></pub-date><volume>32</volume><issue>7</issue><fpage>533</fpage><lpage>536</lpage><history><date date-type="received"><day>30</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>1</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>© The Japanese Society of Hypertension 2009</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Recent studies have established a new regulatory axis in the renin–angiotensin system (RAS). In this axis, angiotensin (Ang)-(1–7) is finally produced from Ang I or Ang II by the catalytic activity of angiotensin-converting enzyme 2 (ACE2). Ang-(1–7) shows actions different from those of AT<sub>1</sub> receptor stimulation, such as vasodilatation, natriuresis, anti-proliferation and an increase in the bradykinin–NO (nitric oxide) system. As the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I, this axis is possibly acting as a counter-regulatory system against the ACE/Ang II/AT<sub>1</sub> receptor axis. The signaling pathway of the ACE2–Ang-(1–7) axis has not yet been totally and clearly understood. However, a recent report suggests that the Mas oncogene acts as a receptor for Ang-(1–7). Intracellular signaling through Mas is not clear yet. Several factors such as Akt phosphorylation, protein kinase C activation and mitogen-activated protein (MAP) kinase inhibition seem to be involved in this signaling pathway. Further investigations are needed to clarify the regulation and mechanism of action of ACE2 and Ang-(1–7). However, this second axis through ACE2 and Ang-(1–7) in RAS can be an important target for the therapy of cardiovascular and metabolic disorders.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>angiotensin</kwd><kwd>angiotensin-(1–7)</kwd><kwd>angiotensin-converting enzyme</kwd><kwd>Mas oncogene</kwd><kwd>receptors</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Japanese Society of Hypertension 2009</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The renin–angiotensin system (RAS) has a critical role in the cardiovascular system. Recent studies on RAS have found various components and have proposed new axes of signaling pathways. In a classical system, angiotensin (Ang) II produced from Ang I by an angiotensin-converting enzyme (ACE) is a strong bioactive substance. Ang II binds to two major types of receptors, namely, Ang II type 1 (AT<sub>1</sub>) and Ang II type 2 (AT<sub>2</sub>) receptors,<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> the signaling pathways of which have been well studied, including in the identification of new signaling-related molecules, such as AT<sub>1</sub> receptor-associated protein (ATRAP)<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> and AT<sub>2</sub> receptor-interacting protein (ATIP).<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> In cardiovascular diseases, AT<sub>2</sub>-receptor stimulation seems to antagonize the signaling associated with AT<sub>1</sub>-receptor stimulation. As the binding affinity of Ang II for the AT<sub>2</sub> receptor does not differ from that for the AT<sub>1</sub> receptor, it is considered that AT<sub>2</sub>-receptor stimulation contributes to the beneficial actions of AT<sub>1</sub>-receptor blockers (ARBs).<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> In this context, AT<sub>2</sub>-receptor agonists, such as compound 21, have been newly developed and are expected to function as useful agents against pathological disorders in the future.<sup><xref ref-type="bibr" rid="CR5">5</xref></sup></p><p id="Par3">Recently, a new axis of RAS has been established. In this axis, Ang I is finally converted to Ang-(1–7) by the catalytic activity of ACE2.<sup><xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref></sup> The mechanisms of action of Ang-(1–7) are still being investigated by many research groups. Santos <italic>et al.</italic><sup><xref ref-type="bibr" rid="CR7">7</xref></sup> reported that the Mas oncogene is a receptor for Ang-(1–7). There are an increasing number of reports on the role of ACE2, Ang-(1–7) and Mas in the cardiovascular system. In this review, an outline of the role and function of ACE2 with the Ang-(1–7) pathway is discussed in comparison with the classical ACE–Ang II–AT<sub>1</sub> receptor axis.</p></sec><sec id="Sec2"><title>ACE, Ang II and angiotensin-II receptors—classical RAS axis</title><p id="Par4">Ang II is a well-known bioactive substance involved in the regulation of blood pressure. Ang II is involved in the exaggeration of cardiovascular disease.<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> Recent studies indicate that Ang II is also involved in the onset of diabetes and metabolic disorders.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> In classical RAS, Ang II is produced from Ang I by the action of ACE. This classical axis can be called as the ACE–AngII–AT<sub>1</sub> receptor axis. Such findings are closely related to the development of RAS inhibitors, such as the ACE inhibitor and ARB. The major receptor subtypes for Ang II are the AT<sub>1</sub> and AT<sub>2</sub> receptors. The AT<sub>1</sub> receptor was cloned in 1991, and this finding has contributed to the development of ARBs and accelerated basic and clinical researches.<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> The distribution of the AT<sub>1</sub> receptor covers most organs, whereas AT<sub>2</sub>-receptor expression is observed in only a few organs after birth and is upregulated in pathological states.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> AT<sub>1</sub>-receptor stimulation mediates the classical major actions of Ang II, and large clinical trials and basic researches have established the concept of the cardiovascular continuum proposed by Dzau <italic>et al.</italic><sup><xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref></sup> AT<sub>1</sub>-receptor stimulation is in fact known to exert hypertension, stroke, cardiovascular events and renal diseases (<xref rid="Fig1" ref-type="fig">Figure 1</xref>). It has also been reported that the blockade of AT<sub>1</sub> receptor promotes longevity.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup><fig id="Fig1"><label>Figure 1</label><caption><p>The role of AT<sub>1</sub> receptor stimulation in hypertension and organ damage. NO, nitric oxide; CKD, chronic kidney disease.</p></caption><graphic xlink:href="41440_2009_Article_BFhr200974_Fig1_HTML" id="d29e357"></graphic></fig></p><p id="Par5">In recent years, efforts have been carried out to produce the inhibitor of RAS. The first trial to produce a renin inhibitor did not succeed for clinical use because of chemical and technical difficulties. However, these efforts produced the ACE inhibitor. This success triggered the development of new RAS inhibitors. ACE inhibitors have some adverse effects, such as coughing. In addition, chronic administration of an ACE inhibitor showed an escape phenomenon, in which the inhibitory action of the ACE inhibitor is strongly attenuated. To solve such problems, ARB has been developed as the second RAS inhibitor. As most actions of Ang II are mediated through the AT<sub>1</sub> receptor, the non-peptide ARB is available and widely used in the treatment of hypertension, and in cardiovascular and renal diseases.</p><p id="Par6">Ang II acts mainly through AT<sub>1</sub> receptors, using various signaling mechanisms. For example, AT<sub>1</sub>-receptor stimulation increases the influx of extracellular Ca<sup>2+</sup> and mobilization of intracellular Ca<sup>2+</sup>. An increase in the intracellular Ca<sup>2+</sup> level activates acute responses, such as vascular smooth-muscle contraction, and also activates various kinases, including the mitogen-activated protein (MAP) kinase pathway, to induce cell-proliferation signaling. AT<sub>1</sub>-receptor stimulation seems to activate the EGF receptor in the plasma membrane. Therefore, a part of the action caused by AT<sub>1</sub>-receptor stimulation is similar to that caused by Ca<sup>2+</sup>-mobilizing hormones and by the EGF family. In contrast, signaling mediated by AT<sub>2</sub>-receptor stimulation is transferred mainly by phosphatases.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Therefore, the action of AT<sub>2</sub>-receptor stimulation is considered to be antagonized against AT<sub>1</sub>-receptor-mediated signaling. In fact, an antagonizing action or the counter-regulation of AT<sub>2</sub>-receptor stimulation has been reported previously.<sup><xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref></sup></p></sec><sec id="Sec3"><title>Roles of ACE2, Ang-(1–7) and the Mas axis—a new RAS pathway</title><p id="Par7">Possible effects such as vasodilation mediated by Ang-(1–7) have been reported; however, the mechanisms leading to Ang-(1–7) production and its receptor were unclear, resulting in the delay of Ang-(1–7)-based researches. Recent reports show that Ang-(1–7) is produced by ACE2 activity.<sup><xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref></sup> ACE2 is reported to be highly expressed in the heart, kidney and testis. ACE2 is a membrane-associated hydrolase and it hydrolyzes Ang I to Ang-(1–9) and Ang II to Ang-(1–7) (<xref rid="Fig2" ref-type="fig">Figure 2</xref>).<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> As Ang-(1–9) can be converted to Ang-(1–7) by ACE or by other peptidases, ACE2 facilitates Ang-(1–7) production by two separate pathways.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> Ang-(1–7) loses only one amino acid from Ang II. It might be possible that Ang-(1–7) is a degradation product of Ang II and one of the inactivation mechanisms of Ang II. However, recent studies indicate that Ang-(1–7) has more active roles in RAS. Ang-(1–7) causes vasodilation, which antagonizes AT<sub>1</sub>-receptor stimulation-mediated vasoconstriction. This effect seemed to be mediated by the bradykinin–NO (nitric oxide) pathway.<sup><xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref></sup> Accordingly, these results suggest that Ang-(1–7) antagonized the pressor effect of AT<sub>1</sub>-receptor stimulation, suggesting that it may act as a kind of AT<sub>1</sub>-receptor antagonist, thereby resulting in a blood-pressure-lowering effect and an organ-protective effect, such as a reduction of cardiac hypertrophy and fibrosis and renal damage (<xref rid="Fig3" ref-type="fig">Figure 3</xref>). It is reported that a lack of ACE2 accelerates the pressure-overload-induced cardiac dysfunction.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> On the other hand, the Ang-(1–7) agonist, AVE0991, was cardioprotective in diabetic rats.<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> In addition, Ang-(1–7) potentiates bradykinin, either through an AT<sub>2</sub>-receptor-dependent mechanism or through the inhibition of ACE.<sup><xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref></sup> Recent studies have also shown that Ang-(1–7), similar to ACE inhibitors, potentiates the effect of bradykinin by inhibiting the desensitization of its receptor.<sup><xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref></sup> It has been discovered that the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I,<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> suggesting that this second arm of the system acts as a counter-regulator of the first arm. Previous reports suggest that olmesartan, an ARB, increased the plasma concentration of Ang-(1–7) and the cardiac ACE2-expression level.<sup><xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref></sup> Another ARB, losartan, also induced similar changes; however, its dose was 100-fold higher than that of olmesartan,<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> suggesting that this effect of ARB is not a class effect. A more detailed analysis could show the regulation of ACE2 and Mas, which could contribute toward a new drug discovery for regulating RAS.<fig id="Fig2"><label>Figure 2</label><caption><p>The production of angiotensin-(1–7) by the angiotensin-converting enzyme 2 (ACE2).</p></caption><graphic xlink:href="41440_2009_Article_BFhr200974_Fig2_HTML" id="d29e512"></graphic></fig><fig id="Fig3"><label>Figure 3</label><caption><p>Action of AT<sub>1</sub> and AT<sub>2</sub> receptors and Mas-mediated signaling. AT<sub>1</sub>, angiotensin-II type-1 receptor; AT<sub>2</sub>, angiotensin-II type-2 receptor; NO, nitric oxide.</p></caption><graphic xlink:href="41440_2009_Article_BFhr200974_Fig3_HTML" id="d29e533"></graphic></fig></p><p id="Par8">Recent studies on the function of ACE2 suggest that ACE2 has an important role in the severity of lung failure, such as in acute respiratory distress syndrome (ARDS) or in acute lung injury.<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> Moreover, it has been shown that the severe acute respiratory syndrome (SARS) corona virus utilizes ACE2 as an essential receptor for cell fusion and for <italic>in vivo</italic> infections, suggesting that ACE2 contributes to SARS pathogenesis.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> These results indicate that ACE2 activity has an important role not only in cardiovascular diseases but also in damages or dysfunctions of other organs. We can expect the further studies on ACE2 functions to contribute toward a new therapy for organ damages that target this enzyme.</p><p id="Par9">A recent report suggests that the <italic>Mas</italic> oncogene acts as a receptor for Ang-(1–7).<sup><xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref></sup> Mas is a class of G-protein-coupled receptor containing 325 amino-acid residues. The expression of Mas is abundantly expressed in the brain and testis. Low levels of Mas expression were also observed in other tissues, such as in the heart, kidney, lung, liver, spleen, tongue and in the skeletal muscle.<sup><xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref></sup> The studies using Mas-deficient mice showed an impairment of cardiac functions in these mice.<sup><xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref></sup> Recent studies suggest that Rac 1, c-Jun NH<sub>2</sub>-terminal kinase (JNK), p38 MAP kinase and the activation of phospholipase C might be involved in Mas-mediated signaling. One of the major pathways of Mas signaling in the cardiovascular system is the phosphorylation of Akt. Moreover, in cardiomyocytes, an inhibition of MAP kinase activation by Ang-(1–7) can be blocked by antisense oligonucleotides against Mas.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> More detailed research works can show the Mas functions more clearly.</p></sec><sec id="Sec4"><title>Perspectives of the ACE2–Ang-(1–7)–Mas axis in clinical field</title><p id="Par10">In recent years, several classes of RAS inhibitors have been developed and these inhibitors are effective in hypertensive patients and in hypertension-associated pathological disorders. ACE inhibitors, ARBs and renin inhibitors are already available for hypertensive patients. Moreover, the AT<sub>2</sub>-receptor agonists, such as compound 21, could be useful in the future. In previous studies, the detailed mechanism of the regulation of the ACE2–Ang-(1–7)–Mas axis was not clearly stated. However, it has been clarified that this pathway acts as a counter-regulation system against the ACE–Ang II–AT<sub>1</sub> receptor pathway. Therefore, it is suggested that the ACE2–Ang-(1–7)–Mas axis could become a new target for the therapy of circulatory disorders and adult diseases, including that of the metabolic syndrome. The total effects of RAS seem to stand on the balance between ACE and ACE2 activities (<xref rid="Fig4" ref-type="fig">Figure 4</xref>). In this respect, it could be considered that the classical ACE–Ang II–AT<sub>1</sub> receptor axis plays as a ‘devil’ and the ‘ACE2–Ang-(1–7)–Mas axis’ plays as an angel for fruitful aging in RAS through blood pressure lowering and organ protection.<fig id="Fig4"><label>Figure 4</label><caption><p>The balance between ACE and ACE2 activities affects cardiovascular disorders. ACE, angiotensin-converting enzyme; Ang, angiotensin; AT<sub>1</sub>, angiotensin-II type-1 receptor; AT<sub>2</sub>, angiotensin-II type-2 receptor.</p></caption><graphic xlink:href="41440_2009_Article_BFhr200974_Fig4_HTML" id="d29e612"></graphic></fig></p></sec><sec id="Sec5"><title>Conflict of interest</title><p id="Par11">The authors declare no conflict of interest.</p></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Gasparo</surname><given-names>M</given-names></name><name><surname>Catt</surname><given-names>KJ</given-names></name><name><surname>Inagami</surname><given-names>T</given-names></name><name><surname>Wright</surname><given-names>JW</given-names></name><name><surname>Unger</surname><given-names>T</given-names></name></person-group><article-title>International union of pharmacology. XXIII. The angiotensin II receptors</article-title><source>Pharmacol Rev</source><year>2000</year><volume>52</volume><fpage>415</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">10977869</pub-id></element-citation></ref><ref id="CR2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daviet</surname><given-names>L</given-names></name><name><surname>Lehtonen</surname><given-names>JY</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Griese</surname><given-names>DP</given-names></name><name><surname>Horiuchi</surname><given-names>M</given-names></name><name><surname>Dzau</surname><given-names>VJ</given-names></name></person-group><article-title>Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>17058</fpage><lpage>17062</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.24.17058</pub-id><pub-id pub-id-type="pmid">10358057</pub-id></element-citation></ref><ref id="CR3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nouet</surname><given-names>S</given-names></name><name><surname>Amzallag</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>JM</given-names></name><name><surname>Louis</surname><given-names>S</given-names></name><name><surname>Seitz</surname><given-names>I</given-names></name><name><surname>Cui</surname><given-names>TX</given-names></name><name><surname>Alleaume</surname><given-names>AM</given-names></name><name><surname>Di Benedetto</surname><given-names>M</given-names></name><name><surname>Boden</surname><given-names>C</given-names></name><name><surname>Masson</surname><given-names>M</given-names></name><name><surname>Strosberg</surname><given-names>AD</given-names></name><name><surname>Horiuchi</surname><given-names>M</given-names></name><name><surname>Couraud</surname><given-names>PO</given-names></name><name><surname>Nahmias</surname><given-names>C</given-names></name></person-group><article-title>Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT<sub>2</sub> receptor-interacting protein, ATIP</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>28989</fpage><lpage>28997</lpage><pub-id pub-id-type="doi">10.1074/jbc.M403880200</pub-id><pub-id pub-id-type="pmid">15123706</pub-id></element-citation></ref><ref id="CR4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzau</surname><given-names>V</given-names></name></person-group><article-title>The cardiovascular continuum and renin-angiotensin-aldosterone system blockade</article-title><source>J Hypertens Suppl</source><year>2005</year><volume>23</volume><fpage>S9</fpage><lpage>S17</lpage><pub-id pub-id-type="doi">10.1097/01.hjh.0000165623.72310.dd</pub-id><pub-id pub-id-type="pmid">15821452</pub-id></element-citation></ref><ref id="CR5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaschina</surname><given-names>E</given-names></name><name><surname>Grzesiak</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Foryst-Ludwig</surname><given-names>A</given-names></name><name><surname>Timm</surname><given-names>M</given-names></name><name><surname>Rompe</surname><given-names>F</given-names></name><name><surname>Sommerfeld</surname><given-names>M</given-names></name><name><surname>Kemnitz</surname><given-names>UR</given-names></name><name><surname>Curato</surname><given-names>C</given-names></name><name><surname>Namsolleck</surname><given-names>P</given-names></name><name><surname>Tschöpe</surname><given-names>C</given-names></name><name><surname>Hallberg</surname><given-names>A</given-names></name><name><surname>Alterman</surname><given-names>M</given-names></name><name><surname>Hucko</surname><given-names>T</given-names></name><name><surname>Paetsch</surname><given-names>I</given-names></name><name><surname>Dietrich</surname><given-names>T</given-names></name><name><surname>Schnackenburg</surname><given-names>B</given-names></name><name><surname>Graf</surname><given-names>K</given-names></name><name><surname>Dahlöf</surname><given-names>B</given-names></name><name><surname>Kintscher</surname><given-names>U</given-names></name><name><surname>Unger</surname><given-names>T</given-names></name><name><surname>Steckelings</surname><given-names>UM</given-names></name></person-group><article-title>Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?</article-title><source>Circulation</source><year>2008</year><volume>118</volume><fpage>2523</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.784868</pub-id><pub-id pub-id-type="pmid">19029468</pub-id></element-citation></ref><ref id="CR6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tipnis</surname><given-names>SR</given-names></name><name><surname>Hooper</surname><given-names>NM</given-names></name><name><surname>Hyde</surname><given-names>R</given-names></name><name><surname>Karran</surname><given-names>E</given-names></name><name><surname>Christie</surname><given-names>G</given-names></name><name><surname>Turner</surname><given-names>AJ</given-names></name></person-group><article-title>A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>33238</fpage><lpage>33243</lpage><pub-id pub-id-type="doi">10.1074/jbc.M002615200</pub-id><pub-id pub-id-type="pmid">10924499</pub-id></element-citation></ref><ref id="CR7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>RA</given-names></name><name><surname>Ferreira</surname><given-names>AJ</given-names></name><name><surname>E Silva</surname><given-names>AC</given-names></name></person-group><article-title>Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis</article-title><source>Exp Physiol</source><year>2008</year><volume>93</volume><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1113/expphysiol.2008.042002</pub-id><pub-id pub-id-type="pmid">18310257</pub-id></element-citation></ref><ref id="CR8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>WJ</given-names></name><name><surname>Meyer</surname><given-names>PM</given-names></name></person-group><article-title>Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis</article-title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60108-1</pub-id><pub-id pub-id-type="pmid">17240286</pub-id></element-citation></ref><ref id="CR9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>TJ</given-names></name><name><surname>Alexander</surname><given-names>RW</given-names></name><name><surname>Griendling</surname><given-names>KK</given-names></name><name><surname>Runge</surname><given-names>MS</given-names></name><name><surname>Bernstein</surname><given-names>KE</given-names></name></person-group><article-title>Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor</article-title><source>Nature</source><year>1991</year><volume>351</volume><fpage>233</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/351233a0</pub-id><pub-id pub-id-type="pmid">2041570</pub-id></element-citation></ref><ref id="CR10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzau</surname><given-names>VJ</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Hayes</surname><given-names>DL</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Plutzky</surname><given-names>J</given-names></name><name><surname>Popma</surname><given-names>JJ</given-names></name><name><surname>Stevenson</surname><given-names>W</given-names></name></person-group><article-title>The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>2850</fpage><lpage>2870</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.655688</pub-id><pub-id pub-id-type="pmid">17179034</pub-id></element-citation></ref><ref id="CR11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzau</surname><given-names>VJ</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Hayes</surname><given-names>DL</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Plutzky</surname><given-names>J</given-names></name><name><surname>Popma</surname><given-names>JJ</given-names></name><name><surname>Stevenson</surname><given-names>W</given-names></name></person-group><article-title>The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>2871</fpage><lpage>2891</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.655761</pub-id><pub-id pub-id-type="pmid">17179035</pub-id></element-citation></ref><ref id="CR12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benigni</surname><given-names>A</given-names></name><name><surname>Corna</surname><given-names>D</given-names></name><name><surname>Zoja</surname><given-names>C</given-names></name><name><surname>Sonzogni</surname><given-names>A</given-names></name><name><surname>Latini</surname><given-names>R</given-names></name><name><surname>Salio</surname><given-names>M</given-names></name><name><surname>Conti</surname><given-names>S</given-names></name><name><surname>Rottoli</surname><given-names>D</given-names></name><name><surname>Longaretti</surname><given-names>L</given-names></name><name><surname>Cassis</surname><given-names>P</given-names></name><name><surname>Morigi</surname><given-names>M</given-names></name><name><surname>Coffman</surname><given-names>TM</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name></person-group><article-title>Disruption of the Ang II type 1 receptor promotes longevity in mice</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><fpage>524</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1172/JCI36703</pub-id><pub-id pub-id-type="pmid">19197138</pub-id></element-citation></ref><ref id="CR13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horiuchi</surname><given-names>M</given-names></name><name><surname>Hayashida</surname><given-names>W</given-names></name><name><surname>Akishita</surname><given-names>M</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Daviet</surname><given-names>L</given-names></name><name><surname>Lehtonen</surname><given-names>JY</given-names></name><name><surname>Dzau</surname><given-names>VJ</given-names></name></person-group><article-title>Stimulation of different subtypes of angiotensin II receptors, AT<sub>1</sub> and AT<sub>2</sub> receptors, regulates STAT activation by negative crosstalk</article-title><source>Circ Res</source><year>1999</year><volume>84</volume><fpage>876</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1161/01.RES.84.8.876</pub-id><pub-id pub-id-type="pmid">10222333</pub-id></element-citation></ref><ref id="CR14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>ES</given-names></name><name><surname>Vinh</surname><given-names>A</given-names></name><name><surname>McCarthy</surname><given-names>CA</given-names></name><name><surname>Gaspari</surname><given-names>TA</given-names></name><name><surname>Widdop</surname><given-names>RE</given-names></name></person-group><article-title>AT<sub>2</sub> receptors: functional relevance in cardiovascular disease</article-title><source>Pharmacol Ther</source><year>2008</year><volume>120</volume><fpage>292</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.08.009</pub-id><pub-id pub-id-type="pmid">18804122</pub-id></element-citation></ref><ref id="CR15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>RM</given-names></name><name><surname>Padia</surname><given-names>SH</given-names></name></person-group><article-title>Angiotensin AT<sub>2</sub> receptors: control of renal sodium excretion and blood pressure</article-title><source>Trends Endocrinol Metab</source><year>2008</year><volume>19</volume><fpage>84</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2008.01.003</pub-id><pub-id pub-id-type="pmid">18294862</pub-id></element-citation></ref><ref id="CR16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donoghue</surname><given-names>M</given-names></name><name><surname>Hsieh</surname><given-names>F</given-names></name><name><surname>Baronas</surname><given-names>E</given-names></name><name><surname>Godbout</surname><given-names>K</given-names></name><name><surname>Gosselin</surname><given-names>M</given-names></name><name><surname>Stagliano</surname><given-names>N</given-names></name><name><surname>Donovan</surname><given-names>M</given-names></name><name><surname>Woolf</surname><given-names>B</given-names></name><name><surname>Robison</surname><given-names>K</given-names></name><name><surname>Jeyaseelan</surname><given-names>R</given-names></name><name><surname>Breitbart</surname><given-names>RE</given-names></name><name><surname>Acton</surname><given-names>S</given-names></name></person-group><article-title>A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9</article-title><source>Circ Res</source><year>2000</year><volume>87</volume><fpage>E1</fpage><lpage>E9</lpage><pub-id pub-id-type="doi">10.1161/01.RES.87.5.e1</pub-id><pub-id pub-id-type="pmid">10969042</pub-id></element-citation></ref><ref id="CR17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vickers</surname><given-names>C</given-names></name><name><surname>Hales</surname><given-names>P</given-names></name><name><surname>Kaushik</surname><given-names>V</given-names></name><name><surname>Dick</surname><given-names>L</given-names></name><name><surname>Gavin</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Godbout</surname><given-names>K</given-names></name><name><surname>Parsons</surname><given-names>T</given-names></name><name><surname>Baronas</surname><given-names>E</given-names></name><name><surname>Hsieh</surname><given-names>F</given-names></name><name><surname>Acton</surname><given-names>S</given-names></name><name><surname>Patane</surname><given-names>M</given-names></name><name><surname>Nichols</surname><given-names>A</given-names></name><name><surname>Tummino</surname><given-names>P</given-names></name></person-group><article-title>Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>14838</fpage><lpage>14843</lpage><pub-id pub-id-type="doi">10.1074/jbc.M200581200</pub-id><pub-id pub-id-type="pmid">11815627</pub-id></element-citation></ref><ref id="CR18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrario</surname><given-names>CM</given-names></name><name><surname>Chappell</surname><given-names>MC</given-names></name><name><surname>Tallant</surname><given-names>EA</given-names></name><name><surname>Brosnihan</surname><given-names>KB</given-names></name><name><surname>Diz</surname><given-names>DI</given-names></name></person-group><article-title>Counterregulatory actions of angiotensin-(1-7)</article-title><source>Hypertension</source><year>1997</year><volume>30</volume><fpage>535</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.30.3.535</pub-id><pub-id pub-id-type="pmid">9322978</pub-id></element-citation></ref><ref id="CR19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roks</surname><given-names>AJ</given-names></name><name><surname>van Geel</surname><given-names>PP</given-names></name><name><surname>Pinto</surname><given-names>YM</given-names></name><name><surname>Buikema</surname><given-names>H</given-names></name><name><surname>Henning</surname><given-names>RH</given-names></name><name><surname>de Zeeuw</surname><given-names>D</given-names></name><name><surname>van Gilst</surname><given-names>WH</given-names></name></person-group><article-title>Angiotensin-(1-7) is a modulator of the human renin-angiotensin system</article-title><source>Hypertension</source><year>1999</year><volume>34</volume><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.34.2.296</pub-id><pub-id pub-id-type="pmid">10454457</pub-id></element-citation></ref><ref id="CR20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brosnihihan</surname><given-names>KB</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Ferrario</surname><given-names>CM</given-names></name></person-group><article-title>Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide</article-title><source>Hypertension</source><year>1996</year><volume>27</volume><fpage>523</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.27.3.523</pub-id><pub-id pub-id-type="pmid">8613197</pub-id></element-citation></ref><ref id="CR21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Ohishi</surname><given-names>M</given-names></name><name><surname>Katsuya</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>N</given-names></name><name><surname>Ikushima</surname><given-names>M</given-names></name><name><surname>Kaibe</surname><given-names>M</given-names></name><name><surname>Tatara</surname><given-names>Y</given-names></name><name><surname>Shiota</surname><given-names>A</given-names></name><name><surname>Sugano</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>S</given-names></name><name><surname>Rakugi</surname><given-names>H</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name></person-group><article-title>Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II</article-title><source>Hypertension</source><year>2006</year><volume>47</volume><fpage>718</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000205833.89478.5b</pub-id><pub-id pub-id-type="pmid">16505206</pub-id></element-citation></ref><ref id="CR22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebermann</surname><given-names>L</given-names></name><name><surname>Spillmann</surname><given-names>F</given-names></name><name><surname>Sidiropoulos</surname><given-names>M</given-names></name><name><surname>Escher</surname><given-names>F</given-names></name><name><surname>Heringer-Walther</surname><given-names>S</given-names></name><name><surname>Schultheiss</surname><given-names>HP</given-names></name><name><surname>Tschöpe</surname><given-names>C</given-names></name><name><surname>Walther</surname><given-names>T</given-names></name></person-group><article-title>The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats</article-title><source>Eur J Pharmacol</source><year>2008</year><volume>590</volume><fpage>276</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2008.05.024</pub-id><pub-id pub-id-type="pmid">18571157</pub-id></element-citation></ref><ref id="CR23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorelik</surname><given-names>G</given-names></name><name><surname>Carbini</surname><given-names>LA</given-names></name><name><surname>Scicli</surname><given-names>AG</given-names></name></person-group><article-title>Angiotensin-(1-7) induces bradykinin-mediated relaxation in porcine coronary artery</article-title><source>J Pharmacol Exp Ther</source><year>1998</year><volume>286</volume><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">9655885</pub-id></element-citation></ref><ref id="CR24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deddish</surname><given-names>PA</given-names></name><name><surname>Marcic</surname><given-names>B</given-names></name><name><surname>Jackman</surname><given-names>HL</given-names></name><name><surname>Wang</surname><given-names>H-Z</given-names></name><name><surname>Skidgel</surname><given-names>RA</given-names></name><name><surname>Erdos</surname><given-names>EG</given-names></name></person-group><article-title>N-domain–specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotenisn-(1-7) and keto-ACE</article-title><source>Hypertension</source><year>1998</year><volume>31</volume><fpage>912</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.31.4.912</pub-id><pub-id pub-id-type="pmid">9535414</pub-id></element-citation></ref><ref id="CR25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minshall</surname><given-names>RD</given-names></name><name><surname>Tan</surname><given-names>F</given-names></name><name><surname>Nakamura</surname><given-names>F</given-names></name><name><surname>Rabito</surname><given-names>SF</given-names></name><name><surname>Becker</surname><given-names>RP</given-names></name><name><surname>Marcic</surname><given-names>B</given-names></name><name><surname>Erdös</surname><given-names>EG</given-names></name></person-group><article-title>Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells</article-title><source>Circ Res</source><year>1997</year><volume>81</volume><fpage>848</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1161/01.RES.81.5.848</pub-id><pub-id pub-id-type="pmid">9351459</pub-id></element-citation></ref><ref id="CR26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benzing</surname><given-names>T</given-names></name><name><surname>Fleming</surname><given-names>I</given-names></name><name><surname>Blaukat</surname><given-names>A</given-names></name><name><surname>Muller-Esterl</surname><given-names>W</given-names></name><name><surname>Busse</surname><given-names>R</given-names></name></person-group><article-title>Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequenstration of the B2 kinin receptor within the plasma membrane of native endothelial cells</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>2034</fpage><lpage>2040</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.99.15.2034</pub-id><pub-id pub-id-type="pmid">10209009</pub-id></element-citation></ref><ref id="CR27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danser</surname><given-names>AHJ</given-names></name><name><surname>Tom</surname><given-names>B</given-names></name><name><surname>de Vries</surname><given-names>R</given-names></name><name><surname>Saxena</surname><given-names>PR</given-names></name></person-group><article-title>L-NAME-resistant bradykinin-induced relaxation in porcine coronary arteries is NO-dependent: effect of ACE inhibition</article-title><source>Br J Pharmacol</source><year>2000</year><volume>131</volume><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0703555</pub-id><pub-id pub-id-type="pmid">10991911</pub-id></element-citation></ref><ref id="CR28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishiyama</surname><given-names>Y</given-names></name><name><surname>Gallagher</surname><given-names>PE</given-names></name><name><surname>Averill</surname><given-names>DB</given-names></name><name><surname>Tallant</surname><given-names>EA</given-names></name><name><surname>Brosnihan</surname><given-names>KB</given-names></name><name><surname>Ferrario</surname><given-names>CM</given-names></name></person-group><article-title>Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors</article-title><source>Hypertension</source><year>2004</year><volume>43</volume><fpage>970</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000124667.34652.1a</pub-id><pub-id pub-id-type="pmid">15007027</pub-id></element-citation></ref><ref id="CR29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agata</surname><given-names>J</given-names></name><name><surname>Ura</surname><given-names>N</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Shinshi</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Hyakkoku</surname><given-names>M</given-names></name><name><surname>Taniguchi</surname><given-names>S</given-names></name><name><surname>Shimamoto</surname><given-names>K</given-names></name></person-group><article-title>Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme</article-title><source>Hypertens Res</source><year>2006</year><volume>29</volume><fpage>865</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1291/hypres.29.865</pub-id><pub-id pub-id-type="pmid">17345786</pub-id></element-citation></ref><ref id="CR30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><article-title>The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice</article-title><source>Exp Physiol</source><year>2008</year><volume>93</volume><fpage>543</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1113/expphysiol.2007.040048</pub-id><pub-id pub-id-type="pmid">18448662</pub-id></element-citation></ref><ref id="CR31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><article-title>Lessons from SARS: control of acute lung failure by the SARS receptor ACE2</article-title><source>J Mol Med</source><year>2006</year><volume>84</volume><fpage>814</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1007/s00109-006-0094-9</pub-id><pub-id pub-id-type="pmid">16988814</pub-id></element-citation></ref><ref id="CR32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>RA</given-names></name><name><surname>Simoes e Silva</surname><given-names>AC</given-names></name><name><surname>Maric</surname><given-names>C</given-names></name><name><surname>Silva</surname><given-names>DM</given-names></name><name><surname>Machado</surname><given-names>RP</given-names></name><name><surname>de Buhr</surname><given-names>I</given-names></name><name><surname>Heringer-Walther</surname><given-names>S</given-names></name><name><surname>Pinheiro</surname><given-names>SV</given-names></name><name><surname>Lopes</surname><given-names>MT</given-names></name><name><surname>Bader</surname><given-names>M</given-names></name><name><surname>Mendes</surname><given-names>EP</given-names></name><name><surname>Lemos</surname><given-names>VS</given-names></name><name><surname>Campagnole-Santos</surname><given-names>MJ</given-names></name><name><surname>Schultheiss</surname><given-names>HP</given-names></name><name><surname>Speth</surname><given-names>R</given-names></name><name><surname>Walther</surname><given-names>T</given-names></name></person-group><article-title>Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>8258</fpage><lpage>8263</lpage><pub-id pub-id-type="doi">10.1073/pnas.1432869100</pub-id><pub-id pub-id-type="pmid">12829792</pub-id></element-citation></ref><ref id="CR33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>RA</given-names></name><name><surname>Ferreira</surname><given-names>AJ</given-names></name><name><surname>E Silva</surname><given-names>AC</given-names></name></person-group><article-title>Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis</article-title><source>Exp Physiol</source><year>2008</year><volume>93</volume><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1113/expphysiol.2008.042002</pub-id><pub-id pub-id-type="pmid">18310257</pub-id></element-citation></ref><ref id="CR34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villar</surname><given-names>AJ</given-names></name><name><surname>Pedersen</surname><given-names>RA</given-names></name></person-group><article-title>Parental imprinting of the Mas protooncogene in mouse</article-title><source>Nature Genet</source><year>1994</year><volume>8</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1038/ng1294-373</pub-id><pub-id pub-id-type="pmid">7894489</pub-id></element-citation></ref><ref id="CR35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzger</surname><given-names>R</given-names></name><name><surname>Bader</surname><given-names>M</given-names></name><name><surname>Ludwig</surname><given-names>T</given-names></name><name><surname>Berberich</surname><given-names>C</given-names></name><name><surname>Bunnemann</surname><given-names>B</given-names></name><name><surname>Ganten</surname><given-names>D</given-names></name></person-group><article-title>Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues</article-title><source>FEBS Lett</source><year>1995</year><volume>357</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(94)01292-9</pub-id><pub-id pub-id-type="pmid">8001672</pub-id></element-citation></ref><ref id="CR36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>RA</given-names></name><name><surname>Castro</surname><given-names>CH</given-names></name><name><surname>Gava</surname><given-names>E</given-names></name><name><surname>Pinheiro</surname><given-names>SV</given-names></name><name><surname>Almeida</surname><given-names>AP</given-names></name><name><surname>Paula</surname><given-names>RD</given-names></name><name><surname>Cruz</surname><given-names>JS</given-names></name><name><surname>Ramos</surname><given-names>AS</given-names></name><name><surname>Rosa</surname><given-names>KT</given-names></name><name><surname>Irigoyen</surname><given-names>MC</given-names></name><name><surname>Bader</surname><given-names>M</given-names></name><name><surname>Alenina</surname><given-names>N</given-names></name><name><surname>Kitten</surname><given-names>GT</given-names></name><name><surname>Ferreira</surname><given-names>AJ</given-names></name></person-group><article-title>Impairment of <italic>in vitro</italic> and <italic>in vivo</italic> heart function in angiotensin-(1-7) receptor MAS knockout mice</article-title><source>Hypertension</source><year>2006</year><volume>47</volume><fpage>996</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000215289.51180.5c</pub-id><pub-id pub-id-type="pmid">16567589</pub-id></element-citation></ref><ref id="CR37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>CH</given-names></name><name><surname>Santos</surname><given-names>RA</given-names></name><name><surname>Ferreira</surname><given-names>AJ</given-names></name><name><surname>Bader</surname><given-names>M</given-names></name><name><surname>Alenina</surname><given-names>N</given-names></name><name><surname>Almeida</surname><given-names>AP</given-names></name></person-group><article-title>Effects of genetic deletion of angiotensin-(1-7) receptor Mas on cardiac function during ischemia/reperfusion in the isolated perfused mouse heart</article-title><source>Life Sci</source><year>2006</year><volume>80</volume><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2006.09.007</pub-id><pub-id pub-id-type="pmid">17055538</pub-id></element-citation></ref><ref id="CR38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallant</surname><given-names>EA</given-names></name><name><surname>Ferrario</surname><given-names>CM</given-names></name><name><surname>Gallagher</surname><given-names>PE</given-names></name></person-group><article-title>Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2005</year><volume>289</volume><fpage>H1560</fpage><lpage>H1566</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00941.2004</pub-id><pub-id pub-id-type="pmid">15951342</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000383 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000383 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7091931
|texte= Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:19461648" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |